HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 15 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
NDUFS6
NADH:ubiquinone oxidoreductase subunit S6
Chromosome 5 Β· 5p15.33
NCBI Gene: 4726Ensembl: ENSG00000145494.13HGNC: HGNC:7713UniProt: O75380
74PubMed Papers
21Diseases
3Drugs
39Pathogenic Variants
FUNCTIONAL ROLE
Hub GeneTransporter
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
respiratory chain complex Imitochondrial inner membranemitochondrionmitochondrial electron transport, NADH to ubiquinonemitochondrial complex I deficiencymitochondrial complex I deficiency, nuclear type 9type 2 diabetes mellitusdiabetes mellitus
✦AI Summary

NDUFS6 encodes an accessory subunit of mitochondrial respiratory complex I (CI) that plays a critical role in electron transfer from NADH to ubiquinone within the electron transport chain 1. As a 13 kiloDalton protein localized to the iron-sulfur fraction of CI's peripheral arm, NDUFS6 is essential for proper CI assembly and oxidative phosphorylation 1. While not directly involved in catalysis, NDUFS6 is indispensable for complex I function and cellular energy metabolism 2. Loss of NDUFS6 function causes mitochondrial complex I deficiency, leading to severe mitochondrial diseases including Leigh syndrome and mitochondrial cardiomyopathy characterized by reduced ATP synthesis and increased reactive oxygen species accumulation 123. NDUFS6 mutations have been identified in neonatal lactic acidemia, peripheral neuropathies, and cardiomyopathy patients 45. Beyond disease, NDUFS6 regulates adult stem cell aging through mitochondrial ROS control 6, and selective NDUFS6 inhibition enhances anti-tumor immunity by promoting MHC-I antigen presentation in cancer cells 78. These findings underscore NDUFS6's dual roles in cellular bioenergetics and as a potential therapeutic target.

Sources cited
1
NDUFS6 encodes a 13 kDa subunit of complex I localized to the iron-sulfur fraction; mutations cause complex I deficiency and Leigh syndrome with neonatal lactic acidemia
PMID: 30948790
2
NDUFS6 knockout in heart causes marked complex I deficiency, reduced ATP synthesis, cardiomyopathy, and increased cardiac failure risk; tissue-specific splicing generates variable phenotypes across tissues
PMID: 22474353
3
Cardiac-specific Ndufs6 knockdown causes mitochondrial cardiomyopathy with metabolic perturbation and female-specific disease progression controlled by ATF3
PMID: 40184463
4
NDUFS6 variants identified as causative mutations in pediatric mitochondrial disorder patients through whole-exome sequencing
PMID: 27290639
5
NDUFS6 biallelic variants cause mitochondrial Charcot-Marie-Tooth disease and inherited peripheral neuropathies
PMID: 38549004
6
Downregulation of Ndufs6 accelerates mesenchymal stem cell aging through increased mitochondrial ROS and p53/p21 upregulation; NDUFS6 replenishment rejuvenates senescent cells
PMID: 33323934
7
Selective NDUFS6 deletion increases tumor immunogenicity by promoting MHC-I expression and antigen presentation through pyruvate dehydrogenase-dependent acetyl-CoA accumulation
PMID: 39824999
8
NDUFS6 is a target of m6A methylation by WTAP complex; PRMT1-WTAP-NDUFS6 axis regulates oxidative phosphorylation and multiple myeloma tumorigenesis
PMID: 37558663
Disease Associationsβ“˜21
mitochondrial complex I deficiencyOpen Targets
0.75Strong
mitochondrial complex I deficiency, nuclear type 9Open Targets
0.68Moderate
type 2 diabetes mellitusOpen Targets
0.61Moderate
diabetes mellitusOpen Targets
0.60Moderate
mitochondrial diseaseOpen Targets
0.60Moderate
mitochondrial complex I deficiency, nuclear type 1Open Targets
0.56Moderate
neurodegenerative diseaseOpen Targets
0.52Moderate
polycystic ovary syndromeOpen Targets
0.41Moderate
gestational diabetesOpen Targets
0.41Moderate
Insulin resistanceOpen Targets
0.40Moderate
obesityOpen Targets
0.40Weak
Parkinson diseaseOpen Targets
0.40Weak
prediabetes syndromeOpen Targets
0.40Weak
prostate cancerOpen Targets
0.39Weak
metabolic syndromeOpen Targets
0.39Weak
type 1 diabetes mellitusOpen Targets
0.39Weak
Disorder of lipid metabolismOpen Targets
0.38Weak
agingOpen Targets
0.37Weak
mitochondrial complex I deficiency, nuclear type 19Open Targets
0.37Weak
COVID-19Open Targets
0.36Weak
Mitochondrial complex I deficiency, nuclear type 9UniProt
Pathogenic Variants39
NM_004553.6(NDUFS6):c.185_186del (p.Glu62fs)Likely pathogenic
Mitochondrial complex I deficiency, nuclear type 9|Mitochondrial complex I deficiency
β˜…β˜…β˜†β˜†2026β†’ Residue 62
NM_004553.6(NDUFS6):c.46G>T (p.Glu16Ter)Pathogenic
not provided|Mitochondrial complex I deficiency
β˜…β˜…β˜†β˜†2025β†’ Residue 16
NM_004553.6(NDUFS6):c.320_323del (p.Thr107fs)Pathogenic
not provided|Mitochondrial complex I deficiency, nuclear type 9|Mitochondrial complex I deficiency
β˜…β˜…β˜†β˜†2025β†’ Residue 107
NM_004553.6(NDUFS6):c.67dup (p.Leu23fs)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 23
NM_004553.6(NDUFS6):c.309+5G>APathogenic
Mitochondrial complex I deficiency, nuclear type 9|not provided|Cervical cancer|Mitochondrial complex I deficiency
β˜…β˜…β˜†β˜†2025
NM_004553.6(NDUFS6):c.309+1G>APathogenic
not provided|Mitochondrial complex I deficiency|Mitochondrial complex I deficiency, nuclear type 9
β˜…β˜…β˜†β˜†2024
NM_004553.6(NDUFS6):c.343T>C (p.Cys115Arg)Pathogenic
not provided|Mitochondrial complex I deficiency
β˜…β˜…β˜†β˜†2024β†’ Residue 115
NM_004553.6(NDUFS6):c.32_33dup (p.Asn12Ter)Pathogenic
not provided|Mitochondrial complex I deficiency, nuclear type 9
β˜…β˜…β˜†β˜†2024β†’ Residue 12
NM_004553.6(NDUFS6):c.309+1G>CPathogenic
not provided|Mitochondrial complex I deficiency, nuclear type 9
β˜…β˜…β˜†β˜†2024
NM_004553.6(NDUFS6):c.344G>A (p.Cys115Tyr)Likely pathogenic
Mitochondrial complex I deficiency, nuclear type 9|not provided|Mitochondrial complex I deficiency
β˜…β˜…β˜†β˜†2024β†’ Residue 115
NM_004553.6(NDUFS6):c.309+2T>CPathogenic
not provided|Mitochondrial complex I deficiency, nuclear type 9
β˜…β˜…β˜†β˜†2024
NM_004553.6(NDUFS6):c.109G>T (p.Glu37Ter)Pathogenic
Inborn genetic diseases|not provided|Mitochondrial complex I deficiency, nuclear type 9
β˜…β˜…β˜†β˜†2024β†’ Residue 37
NM_004553.6(NDUFS6):c.187-1G>CLikely pathogenic
Mitochondrial complex I deficiency, nuclear type 9|not provided
β˜…β˜…β˜†β˜†2023
NM_004553.6(NDUFS6):c.242del (p.Glu81fs)Pathogenic
Mitochondrial complex I deficiency, nuclear type 9|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 81
NM_004553.6(NDUFS6):c.309+1G>TPathogenic
Mitochondrial complex I deficiency, nuclear type 9|not provided
β˜…β˜…β˜†β˜†2023
NM_004553.6(NDUFS6):c.344G>T (p.Cys115Phe)Likely pathogenic
Mitochondrial complex I deficiency
β˜…β˜†β˜†β˜†2025β†’ Residue 115
NM_004553.6(NDUFS6):c.187-38_223delLikely pathogenic
Mitochondrial complex I deficiency, nuclear type 9
β˜…β˜†β˜†β˜†2024
NM_004553.6(NDUFS6):c.294del (p.Val99fs)Likely pathogenic
Mitochondrial complex I deficiency
β˜…β˜†β˜†β˜†2024β†’ Residue 99
NM_004553.6(NDUFS6):c.334_359delinsAACAAACAAAAA (p.Cys112fs)Likely pathogenic
Mitochondrial complex I deficiency, nuclear type 9
β˜…β˜†β˜†β˜†2024β†’ Residue 112
NM_004553.6(NDUFS6):c.197dup (p.Asn66fs)Likely pathogenic
Mitochondrial complex I deficiency
β˜…β˜†β˜†β˜†2024β†’ Residue 66
View on ClinVar β†—
Drug Targets3
ME-344Phase I/II
Mitochondrial complex I (NADH dehydrogenase) inhibitor
breast cancer
METFORMINApproved
Mitochondrial complex I (NADH dehydrogenase) inhibitor
diabetes mellitus
METFORMIN HYDROCHLORIDEApproved
Mitochondrial complex I (NADH dehydrogenase) inhibitor
type 2 diabetes mellitus
Related Genes
NDUFA1Protein interaction100%NDUFA2Protein interaction100%NDUFA3Protein interaction100%NDUFA7Protein interaction100%NDUFA8Protein interaction100%NDUFA10Protein interaction100%
Tissue Expression6 tissues
Heart
100%
Liver
78%
Brain
54%
Lung
40%
Bone Marrow
33%
Ovary
27%
Gene Interaction Network
Click a node to explore
NDUFS6NDUFA1NDUFA2NDUFA3NDUFA7NDUFA8NDUFA10
PROTEIN STRUCTURE
Preparing viewer…
PDB5XTB Β· 3.40 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.54LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.99 [0.65–1.54]
RankingsWhere NDUFS6 stands among ~20K protein-coding genes
  • #6,414of 20,598
    Most Researched74
  • #626of 1,025
    FDA-Approved Drug Targets2
  • #1,567of 5,498
    Most Pathogenic Variants39
  • #15,399of 17,882
    Most Constrained (LOEUF)1.54
Genes detectedNDUFS6
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Selective deficiency of mitochondrial respiratory complex I subunits Ndufs4/6 causes tumor immunogenicity.
PMID: 39824999
Nat Cancer Β· 2025
1.00
2
New perspective in diagnostics of mitochondrial disorders: two years' experience with whole-exome sequencing at a national paediatric centre.
PMID: 27290639
J Transl Med Β· 2016
0.90
3
PRMT1 methylation of WTAP promotes multiple myeloma tumorigenesis by activating oxidative phosphorylation via m6A modification of NDUFS6.
PMID: 37558663
Cell Death Dis Β· 2023
0.80
4
NDUFS6 related Leigh syndrome: a case report and review of the literature.
PMID: 30948790
J Hum Genet Β· 2019
0.70
5
Atf3 controls transitioning in female mitochondrial cardiomyopathy as identified by spatial and single-cell transcriptomics.
PMID: 40184463
Sci Adv Β· 2025
0.60